Glancy Prongay & Murray LLP Announces Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors (ACAD)

Glancy
Prongay & Murray LLP (“GPM”) announces that it has commenced an
investigation on behalf of ACADIA Pharmaceuticals Inc. (“ACADIA” or the
“Company”) (NASDAQ: ACAD)
investors concerning the Company and its officers’ possible violations
of federal securities laws.

If you are a shareholder who suffered a loss, click here
to participate.

On April 9, 2018, CNN reported that “[p]hysicians, medical researchers
and other experts told CNN that they worried that [Nuplazid] had been
approved too quickly, based on too little evidence that it was safe or
effective.” On this news, ACADIA’s share price fell more than 23% on
April 9, 2018, thereby injuring investors.

Then, on April 25, 2018, CNN reported that the U.S. Food and Drug
Administration was re-examining the safety of Nuplazid, which was
approved “despite concerns that not enough was known about the drug’s
risks.” On this news, ACADIA’s share price fell nearly 22% on April 25,
2018, thereby further injuring investors.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased ACADIA securities, have information or would like to
learn more about these claims, or have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East,
Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at
888-773-9224, by email to shareholders@glancylaw.com,
or visit our website at www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180713005463/en/

Leave a Comment